Stewart et al. used ultrasensitive single molecule detection technology (Simoa) to prove that the total α-synuclein level in saliva highly matches the total α-synuclein concentration in CSF, and that salivary α-synuclein is reduced by approximately 30% in PD-MCI patients compared to healthy controls (43). This evidence concerns the gene SNCA and Parkinson disease.